LYON, France — The drug zodasiran (formerly ARO-ANG3), which targets the production of a liver protein, substantially lowers triglyceride and a range of lipoprotein levels in patients with mixed hyperlipidemia who are stable on optimal statin therapy, according to ARCHES-2 study investigators. The hepatocyte-targeted small interfering (si) RNA was designed to silence the expression of …
